Nemolizumab Clinical Trials (2026): 22 Studies for Atopic Dermatitis & Moderate-to-Severe Atopic Dermatitis
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
22 Nemolizumab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 11 indications (including Atopic Dermatitis & Moderate-to-Severe Atopic Dermatitis) and 6,388 total planned enrollment. 8 Phase 3 Nemolizumab trials and 9 Phase 2, 2 Phase 4 are listed. 5 Nemolizumab clinical trials are actively recruiting at 20 U.S. sites across 13 states. Most recent activity: NCT07352566 (Jun 2030).
Where to Participate: All Nemolizumab Trial Sites in the U.S. (20 sites across 13 states)
Every actively recruiting Nemolizumabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | Galderma Investigational Site (site# 8893) | Birmingham35244 | NCT07074977 | Map |
| CA | Galderma Investigational Site (site# 8636) | Fountain Valley92708 | NCT07074977 | Map |
| CA | Galderma Investigational Site (site# 8130) | Los Angeles90045 | NCT07074977 | Map |
| CA | Galderma Investigational Site (#9975) | Sacramento95815 | NCT07074977 | Map |
| CA | Galderma Investigational Site (site# 7075) | San Francisco94115 | NCT07074977 | Map |
| FL | Galderma Investigational Site (site# 7054) | Tampa33609 | NCT07074977 | Map |
| KY | Galderma Investigational Site (#7129) | Bowling Green42104 | NCT07074977 | Map |
| MI | Galderma Investigational Site (site# 8743) | Ann Arbor48109 | NCT07074977 | Map |
| MI | Galderma Investigational Site # 8743 | Ann Arbor48109-5000 | NCT07047690 | Map |
| NV | Galderma Investigational Site (site# 8108) | Las Vegas89145 | NCT07074977 | Map |
| NY | Galderma Investigational Site (site# 7110) | New City10956 | NCT07074977 | Map |
| NY | The Skin Center Dermatology Group | New City10956 | NCT07396168 | Map |
| NY | Galderma Investigational Site (#7130) | The Bronx10455 | NCT07074977 | Map |
| ND | Galderma Investigational Site (site# 7111) | Fargo58103 | NCT07074977 | Map |
| OR | Galderma Investigational Site (#8212) | Portland97210 | NCT07074977 | Map |
| PA | Galderma Investigational Site (#8255) | Philadelphia19103 | NCT07074977 | Map |
| TX | Galderma Investigational Site#7096 | Arlington76012 | NCT07047690 | Map |
| TX | Galderma Investigational Site (site# 8003) | Webster77598 | NCT07074977 | Map |
| VA | Galderma Investigational Site (site# 8862) | Fairfax22031 | NCT07074977 | Map |
| WV | Galderma Investigational Site (site# 8725) | Morgantown26505 | NCT07074977 | Map |
Nemolizumab clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | withdrawn | not yet recruiting | Total |
|---|---|---|---|---|---|---|
| P1 | 1 | 1 | ||||
| P2 | 2 | 7 | 9 | |||
| P2/P3 | 1 | 1 | ||||
| P3 | 2 | 5 | 1 | 8 | ||
| P4 | 1 | 1 | 2 | |||
| N/A | 1 | 1 |
Recruiting Nemolizumab clinical trials (5)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07352566 | Utilization of a Microdevice for Psoriasis and Atopic Dermatitis | P4 | Psoriasis | 10 | Aug 2026 |
| NCT03358693 | MSIDMolecular Signatures in Inflammatory Skin Disease | — | Atopic Dermatitis | 300 | Jan 2017 |
| NCT07047690 | A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis | P2 | Systemic Sclerosis | 162 | Feb 2026 |
| NCT07396168 | Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study. | P4 | Lichen Plano-Pilaris | 10 | Feb 2026 |
| NCT07074977 | CPUOProof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO) | P2 | Chronic Pruritus of Unknown Origin | 50 | Oct 2025 |
Nemolizumab clinical trials by indication
Atopic Dermatitis (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03358693 | MSID | N/A | recruiting | Molecular Signatures in Inflammatory Skin Disease |
| NCT04562116 | — | P2 | completed | A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis |
| NCT03921411 | AD | P2 | completed | A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD) |
| NCT03100344 | — | P2 | completed | Dose-ranging Study of Nemolizumab in Atopic Dermatitis |
| NCT01986933 | — | P2 | completed | A Phase 2 Study of CIM331 for Atopic Dermatitis Patients |
Prurigo Nodularis (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04204616 | CD14152 | P3 | active not recruiting | A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) |
| NCT05052983 | — | P3 | completed | A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis |
| NCT04501666 | CD14152 | P3 | completed | Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) |
| NCT04501679 | CD14152 | P3 | completed | A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) |
Moderate-to-Severe Atopic Dermatitis (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03989206 | — | P3 | active not recruiting | Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis |
| NCT04921345 | — | P2 | completed | Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis |
| NCT03989349 | — | P3 | completed | Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis |
| NCT03985943 | — | P3 | completed | Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis |
Systemic Sclerosis (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07047690 | — | P2 | recruiting | A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis |
| NCT05214794 | — | P2 | completed | An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis |
Lichen Plano-Pilaris (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07396168 | — | P4 | recruiting | Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study. |
Psoriasis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07352566 | — | P4 | not yet recruiting | Utilization of a Microdevice for Psoriasis and Atopic Dermatitis |
Chronic Pruritus of Unknown Origin (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07074977 | CPUO | P2 | recruiting | Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO) |
Moderate-to-severe Atopic Dermatitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05056779 | — | P3 | withdrawn | Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable |
Healthy Volunteers (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05405985 | — | P1 | completed | Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber Syringe |
Chronic Kidney Disease Associated Moderate to Severe Pruritus (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05075408 | NIKAIA 1 | P2/P3 | completed | To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus |
Dermatitis, Atopic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04365387 | — | P2 | completed | A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab |
Nemolizumab pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| CD14152 | NCT04204616 | P3 | active not recruiting | Prurigo Nodularis | 500 | — |
| CD14152 | NCT04501666 | P3 | completed | Prurigo Nodularis | 286 | — |
| CD14152 | NCT04501679 | P3 | completed | Prurigo Nodularis | 274 | — |
| CPUO | NCT07074977 | P2 | recruiting | Chronic Pruritus of Unknown Origin | 50 | — |
| AD | NCT03921411 | P2 | completed | Atopic Dermatitis | 20 | — |
Terminated and withdrawn Nemolizumab trials (1)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT05056779withdrawnEfficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable
All Nemolizumab trials (22)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07352566 | Utilization of a Microdevice for Psoriasis and Atopic Dermatitis | P4 | not yet recruiting | 10 | University of California, San Francisco | Aug 2026 | |
| NCT03358693 | MSID | Molecular Signatures in Inflammatory Skin Disease | — | recruiting | 300 | Prof. Dr. Stephan Weidinger | Jan 2017 |
| NCT07047690 | A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis | P2 | recruiting | 162 | Galderma R&D | Feb 2026 | |
| NCT07396168 | Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study. | P4 | recruiting | 10 | The Skin Center Dermatology Group | Feb 2026 | |
| NCT07074977 | CPUO | Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO) | P2 | recruiting | 50 | Galderma R&D | Oct 2025 |
| NCT04204616 | CD14152 | A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) | P3 | active not recruiting | 500 | Galderma R&D | Jan 2021 |
| NCT03989206 | Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis | P3 | active not recruiting | 1,700 | Galderma R&D | Dec 2019 | |
| NCT04921345 | Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis | P2 | completed | 109 | Galderma R&D | Jun 2021 | |
| NCT05214794 | An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis | P2 | completed | 6 | Maruho Co., Ltd. | Apr 2022 | |
| NCT05075408 | NIKAIA 1 | To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus | P2/P3 | completed | 258 | Galderma R&D | Mar 2022 |
| NCT05052983 | A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis | P3 | completed | 34 | Galderma R&D | Jan 2022 | |
| NCT05056779 | Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable | P3 | withdrawn | 0 | Galderma R&D | Jan 2023 | |
| NCT04365387 | A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab | P2 | completed | 242 | Galderma R&D | Mar 2020 | |
| NCT04562116 | A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis | P2 | completed | 17 | Galderma R&D | Dec 2021 | |
| NCT04501666 | CD14152 | Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) | P3 | completed | 286 | Galderma R&D | Sep 2020 |
| NCT05405985 | Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber Syringe | P1 | completed | 192 | Galderma R&D | Aug 2022 | |
| NCT03989349 | Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis | P3 | completed | 787 | Galderma R&D | Jun 2019 | |
| NCT03985943 | Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis | P3 | completed | 941 | Galderma R&D | Jun 2019 | |
| NCT04501679 | CD14152 | A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) | P3 | completed | 274 | Galderma R&D | Aug 2020 |
| NCT03921411 | AD | A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD) | P2 | completed | 20 | Galderma R&D | Apr 2019 |
| NCT03100344 | Dose-ranging Study of Nemolizumab in Atopic Dermatitis | P2 | completed | 226 | Galderma R&D | Jun 2017 | |
| NCT01986933 | A Phase 2 Study of CIM331 for Atopic Dermatitis Patients | P2 | completed | 264 | Chugai Pharmaceutical | Nov 2013 |
Nemolizumab clinical trials: frequently asked questions
- How many Nemolizumab clinical trials are there?
- 22 Nemolizumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 4 are actively recruiting participants. 14 are marked completed.
- Are Nemolizumab clinical trials recruiting in 2026?
- Yes — 4 Nemolizumab trials are actively recruiting in 2026, with 20 U.S. sites across 13 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Nemolizumab being studied for?
- Nemolizumab is being studied for Atopic Dermatitis, Moderate-to-Severe Atopic Dermatitis, Prurigo Nodularis, Systemic Sclerosis, Psoriasis and 6 more. The trials are grouped by indication on this page.
- What phase is Nemolizumab in?
- Nemolizumab clinical trials span 2 Phase 4, 8 Phase 3, 9 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Nemolizumab clinical trials?
- The lead sponsor across the most Nemolizumab trials is Galderma R&D, with 5 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Nemolizumabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: